Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Eligible participants

THANK YOU TO OUR > 500 PARTICIPANTS WHO ARE HELPING TO MAKE THE STUDY A SUCCESS. THE STUDY IS NOW CLOSED FOR NEW PARTICIPANTS.

Your doctor will already have explained to you that you have one of the following disorders but do not require treatment:

  • Early stage Chronic Lymphocytic Leukaemia (CLL),
  • Monoclonal B-cell Lymphocytosis (MBL),
  • Monoclonal Gammopathy of Uncertain Significance (MGUS),
  • Waldenstroms Macroglobulinaemia (WM)
  • Smouldering Myeloma (SM)

As explained previously, some individuals with your condition can develop more serious conditions which do need to be treated.   You have been invited to take part in the study so that you can be monitored and data gathered about your condition over a period of up to 5 years.

We aim to recruit approximately 1650 participants, all of whom have one of these 5 early lymphoproliferative conditions.  Any study participants who experience worsening (progression) of their condition during the study will have additional samples and information collected at that point. 

Doctors and scientists will study blood and bone marrow samples from participants, and compare samples from people in whom the disorder has worsened (progressed) and people in whom the disorder has stayed the same (stable).

This research will help doctors to predict which groups of people might be at increased risk of needing cancer treatment in the future.  This information might also help to develop new treatments for blood and bone marrow cancers.

It is up to you if you wish to take part in the study. The study will be fully explained in this leaflet including what you need to do if you agree to take part. While you’re on the study you will continue to receive any standard monitoring of your condition that you’re already receiving. So, for example, if you’re already having clinic visits or telephone follow-up appointments every 6-12 months those will continue as normal.  Or if the only follow-up you’re currently receiving is through your GP you’ll continue to access care from your GP as usual.  Any visits to take part in the study are in addition to, not instead of, your usual care. 

For further information on eligibility please see inclusion criteria and exclusion criteria. 

To access our patient information leaflet please click here.

In this section